U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07158710) titled 'Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation' on Aug. 06.
Brief Summary: This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK of HSK42360 when given orally in pediatric patients with active BRAF V600 mutation recurrent malignant brain tumors.
Study Start Date: Aug. 15
Study Type: INTERVENTIONAL
Condition:
Malignant Brain Tumors
Intervention:
DRUG: HSK42360
Oral administration, QD/BID
Recruitment Status: RECRUITING
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Dige...